Only some of the damage repair methods require gene therapy, and in the case of allotopic expression to work around mitochondrial damage that is already demonst

Only some of the damage repair methods require gene therapy, and in the case of allotopic expression to work around mitochondrial damage that is already demonstrated in human trials by Gensight. You should look over the linked sub-pages here for an overview of the types of damage and approaches to repair. http://www.sens.org/research/introduction-to-sens-research http://www.sens.org/research/introduction-to-sens-research I'd be more concerned about stem cell replacement therapies and lipofuscin removal as categories than anything requiring gene therapy, since in both cases there are a lot of targets and a lot of work to do. For things like senescent cells and glucosepane cross-links, small molecule therapies will work (and already exist in the former case). In fact all targeted cell killing and specific molecule breakdown needs can probably be addressed sufficiently well via pharmaceuticals for a first generation effort.